The state of New Jersey currently has 8 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/24/2024
Locations: Windsor Dermatology dba Eczema Treatment Center of New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/24/2024
Locations: The Dermatology Center of New Jersey, Bridgewater, New Jersey
Conditions: Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2024
Locations: Continental Clinical Solutions - Cherry Hill, Cherry Hill, New Jersey
Conditions: Atopic Dermatitis
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2024
Locations: Metropolitan Dermatology - Clark, Kenilworth, New Jersey
Conditions: Atopic Dermatitis
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Windsor Dermatology, East Windsor, New Jersey +1 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Dupixent and Narrowband UVB for Atopic Dermatitis
Recruiting
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Eczema Treatment Center of New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Recruiting
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Rao Dermatology, Atlantic Highlands, New Jersey
Conditions: Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Recruiting
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Schweiger Dermatology Group, Hackensack, New Jersey
Conditions: Atopic Dermatitis